Article - 03/04/2019 HKK Bionics empowers hand gripping functions A spin-off from the Ulm University of Applied Sciences is aiming to provide people whose hands have been paralysed due to accident or illness with a new kind of orthopaedic aid. Dominik Hepp and Tobias Knobloch are currently starting serial production of a hand orthosis prototype. The two medical engineers from Ulm, who founded HKK Bionics GmbH in 2017, plan to commence final tests in 2019.https://www.gesundheitsindustrie-bw.de/en/article/news/hkk-bionics-empowers-hand-gripping-functions
Article - 28/03/2019 Supporting the human use of artificial intelligence Artificial intelligence is no longer a vision of the future, but is already in our midst: whether it is parking aids or search engines, we use the technology quite naturally in many areas of daily life. It promises new, unlimited opportunities, but also poses risks. Experts from the Integrata Foundation in Tübingen work on ethical issues and the human use of IT for improving the life of as many people as possible. https://www.gesundheitsindustrie-bw.de/en/article/news/supporting-the-human-use-of-artificial-intelligence
Press release - 26/03/2019 EUR 3 million in series A for the growth and development of Cytena GmbH The High-Tech Gründerfonds (HTGF) and two private investors are convinced of the importance of single-cell isolation for the production of biopharmaceuticals and for genetic analysis in research and diagnostics. EUR 3 million will be invested in the further development of the technology, the expansion of the sales organization and in opening up further applications for Cytena’s single-cell printers.https://www.gesundheitsindustrie-bw.de/en/article/press-release/eur-3-million-in-series-a-for-the-growth-and-development-of-cytena-gmbh
Article - 22/03/2019 Personalised therapies for treating metastasing breast cancer Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
Anniversary - 12/12/2018 15 years of BIOPRO: Pooling competencies – pushing innovations This is the leitmotif of BIOPRO Baden-Württemberg GmbH, which was founded in 2003. 15 years is a good time to pause for a moment and take a look at BIOPRO’s work and achievements. As a central point of contact and wholly-owned subsidiary of the Baden-Württemberg government whose main objective is to promote networking, BIOPRO knows only too well that progress is not made alone, but in collaboration with others.https://www.gesundheitsindustrie-bw.de/en/article/press-release/15-years-of-biopro-pooling-competencies-pushing-innovations
Press release - 03/12/2018 SpinDiag closes second financing round of EUR 3.0 million (USD 3.4 million) to complete product development of its point-of-care screening system for antibiotic-resistant bacteria One year after its seed financing, SpinDiag GmbH closes a second financing round of EUR 3 million (USD 3.4 million) as planned. The financing will enable SpinDiag to complete the product development of its first product for screening for antibiotic-resistant bacteria and to start clinical trials. This will pave the way for regulatory approval in the EU.https://www.gesundheitsindustrie-bw.de/en/article/press-release/spindiag-closes-second-financing-round-of-eur-30-million-usd-34-million-to-complete-product-development-of-its-point-of-care-scr
Press release - 29/11/2018 Hattrick in Freiburg Three researchers at the MPI for Immunobiology and Epigenetics receive millions in funding from the European Research Council. Dominic Grün, Nicola Iovino and Ritwick Sawarkar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg will each be awareded one of the prestigious Consolidator Grants of the European Research Council. This means that 6 million euros in funding will go to fundamental research in Freiburg over the next…https://www.gesundheitsindustrie-bw.de/en/article/press-release/hattrick-in-freiburg
Article - 02/10/2018 Artificial intelligence in the life sciences: machines as assistants Artificial intelligence is currently one of the most innovative issues, but also one of the most controversial research areas. It already has a firm footing in many areas of our everyday life and often we are not even aware of it. Artificial intelligence has long been an integral part of many processes in research and diagnostics in medicine and the life sciences – and it will be even more widely used in the future.https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-intelligence-in-the-life-sciences-machines-as-assistants
Press release - 27/09/2018 Three new Clusters of Excellence for Tübingen University takes next hurdle in the German government’s Excellence Strategy funding program. The University of Tübingen is to have three new Clusters of Excellence.As part of the German government’s Excellence Strategy funding forhigher education research, Tübingen will host new outstanding research networks starting in January 2019. Representatives of Germany’s higher education policymakers announced the decision in Bonn on Thursday.https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-new-clusters-of-excellence-for-tuebingen
Press release - 27/09/2018 One hundred percent success Two Clusters of Excellence for the University of Freiburg: Biological Signalling Studies and Bioinspired Materials Research. It is a major boost to cutting-edge research in Freiburg: in the current Excellence Strategy competition, scientists at the University of Freiburg have been granted two Clusters of Excellence, CIBSS – Centre for Integrative Biological Signalling Studies, and livMatS – Living, Adaptive and Energy-autonomous Materials…https://www.gesundheitsindustrie-bw.de/en/article/press-release/one-hundred-percent-success
Industry report 2018 - 27/09/2018 The healthcare industry – the innovation driver of the 21st century: opportunities and challenges BIOPRO Baden-Württemberg’s new industry report entitled "The Healthcare Industry 2018: Facts and Figures for Baden-Württemberg" has just been published in both German and English. The topic neatly dovetails with the state’s political activities. An evaluation of the region carried out on behalf of the Baden-Württemberg government has clearly recognised the importance of the healthcare sector as a driver of innovation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-healthcare-industry-the-innovation-driver-of-the-21st-century
Cancer immunotherapy - 06/09/2018 The immunogenicity of tumours and the development of new cancer medicines Microsatellite-unstable cancers are characterised by a large number of mutations within short repetitive DNA sequence regions, and can form novel peptides that the human immune system recognises as neoantigens. These cancers represent a starting point for the development of vaccines to prevent them appearing at an early stage of development. Microsatellite instability is particularly frequent in colon and cervical cancers.https://www.gesundheitsindustrie-bw.de/en/article/news/the-immunogenicity-of-tumours-and-the-development-of-new-cancer-medicines
Article - 14/08/2018 Simple and fast: new optical method for analysing living cells The junior researchers Dr. Daniel Geiger, Tobias Neckernuß and Jonas Pfeil from Ulm have developed an innovative method for non-contact real-time analysis of cells and other particles. The analysis involves low data rates and correspondingly little effort. This is what makes the method so attractive for medical applications.https://www.gesundheitsindustrie-bw.de/en/article/news/simple-and-fast-new-optical-method-for-analysing-living-cells
Press release - 27/07/2018 KIT Takes the Next Step: Federal and State Ministries Determined to Push KIT’s Further Development To further support and develop the scientific capacity of Karlsruhe Institute of Technology (KIT), the federal and state governments are determined to take the courageous merger of 2009 to the next level. During their joint visit of KIT today, Federal Minister of Education and Research Anja Karliczek and the Baden-Württemberg Minister for Science, Research and the Arts Theresia Bauer agreed on the next steps. https://www.gesundheitsindustrie-bw.de/en/article/press-release/kit-takes-the-next-step-federal-and-state-ministries-determined-to-push-kits-further-development
Funding Future Insight Prize Funding programme, Funded by: Merck KGaA, Submission deadline: 31/12/2022 https://www.gesundheitsindustrie-bw.de/en/database/funding/future-insight-prize
The Baden-Württemberg healthcare industry Baden-Württemberg – an attractive business location Baden-Württemberg, the state of inventors and thinkers, is one of the leading economic regions in Germany and Europe thanks to an economic landscape that incorporates many small- and medium-sized businesses. The state’s innovative strength is partly based on the scientific excellence of university and non-university research institutions and innovative companies, and partly on its attractiveness as a base for creating and developing companies.…https://www.gesundheitsindustrie-bw.de/en/location/location-bw
Press release - 20/07/2018 First closing at SHS: Medical technology investor raises over €90 million for its fifth fund SHS Gesellschaft für Beteiligungsmanagement has received capital commitments of over €90 million in its fifth fund's first closing. The fifth generation of SHS funds is also focused on the life sciences and medical technology sector, and thus on the growing global healthcare market with innovative and strong players, especially in Germany and Switzerland.https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-closing-at-shs-medical-technology-investor-raises-over-90-million-for-its-fifth-fund
Press release - 04/07/2018 Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy Viscofan BioEngineering, the biomedical business unit of the world market leader for collagenous sausage casings Viscofan announced today that the Spanish Agency for Medicines (AEMPS) has given green light to carry out a clinical phase-I-trial with Viscofan BioEngineering’s first product for regenerative medicine. The novel therapy consisting of stem cells on a collagenous carrier membrane can now be tested on ten patients suffering from severe…https://www.gesundheitsindustrie-bw.de/en/article/press-release/phase-i-trial-approved-for-novel-stem-cell-therapy-for-patients-with-ischemic-cardiomyopathy
Expert interview - 26/06/2018 Genome analyses: "Germany lags behind dramatically" Around 6,000 genetic diseases can be diagnosed using genetic tests. Genetic testing enables the accurate identification of diseases especially when symptoms are unclear, and also allows statements to be made about disease progression. However, restrictive regulations considerably hinder the use of genetic diagnostics. BIOPRO spoke with Dr. Dr. Saskia Biskup, a human genetics specialist and co-founder of the Tübingen-based company CeGaT. https://www.gesundheitsindustrie-bw.de/en/article/news/genome-analyses-germany-lags-behind-dramatically
Article - 29/05/2018 ITAS – Assessing the impact of life science technologies The Karlsruhe Institute for Technology Assessment and Systems Analysis (ITAS) is one of the largest and most renowned institutions in Germany involved in evaluating scientific and technological developments. The institute assesses the impacts and possible effects of new methods from a wide range of scientific fields - including the life sciences.https://www.gesundheitsindustrie-bw.de/en/article/news/assessing-the-impact-of-life-science-technologies
Article - 19/04/2018 New combination therapy for treating stroke patients 30 to 40 percent of all stroke patients suffer from persistent signs of paralysis that prevents them from using the affected hand. The innovative combination of two non-invasive treatment methods is a therapeutic approach with considerable potential for treating severely impaired patients.https://www.gesundheitsindustrie-bw.de/en/article/news/new-combination-therapy-for-treating-stroke-patients
Article - 05/04/2018 Crossing the valley of death with translational cancer research It can take many decades before promising research results become therapies that have a positive effect on cancer patients. Most research projects go adrift somewhere between the laboratory and the bedside in the so-called "valley of death". Projects carried out at the DKFZ show that translational cancer research actually works.https://www.gesundheitsindustrie-bw.de/en/article/news/crossing-the-valley-of-death-with-translational-cancer-research
Article - 19/03/2018 Regenerative medicine: curing rather than simply treating diseases Some scientists refer to the latest developments in the field of regenerative medicine as the "next revolution in medicine". With the help of gene therapies or stem cells, regenerative medicine aims not only to treat disease symptoms, but to cure them at source. Some approaches are already being used to treat patients and several others are close to application.https://www.gesundheitsindustrie-bw.de/en/article/news/regenerative-medicine-curing-rather-than-simply-treating-diseases
Article - 14/03/2018 Patent versus publication: setting up start-ups in the sciences When it comes to universities as start-up incubators, the Massachusetts Institute of Technology (MIT) in the USA is often used as a prime example of entrepreneurial impact. Well over 100 high-tech spin-offs have been set up in the vicinity of the renowned university. Many German universities also offer attractive conditions for scientists with an entrepreneurial spirit. https://www.gesundheitsindustrie-bw.de/en/article/news/patent-versus-publication-setting-up-start-ups-in-the-sciences
Article - 14/02/2018 Animal-free diabetes research with the pancreas chip Quite a number of promising drug candidates for the treatment of diabetes are currently in the pharmaceutical pipeline, including innovative drugs that can stimulate the regeneration of insulin-producing pancreatic cells. However, they will have to be safety tested in animals. Scientists from Ulm University Hospital have now begun to develop a pancreatic chip from stem cells.https://www.gesundheitsindustrie-bw.de/en/article/news/animal-free-diabetes-research-with-the-pancreas-chip